Aug 19, 2025
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Aug 18, 2025
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Aug 13, 2025
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” SeriesVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Aug 20, 2025 03:10 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
4.96
CHANGE
0.04 (0.72%)
